Nuvectis Pharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Cash from operations | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
Shares outstanding 26.5M · Free float 57.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.